Roche’s Virtual Pipeline Event from WFH 2018 World Congress

Glasgow, Wednesday, 23 May 2018
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. increased government pricing pressures;
7. interruptions in production;
8. loss of or inability to obtain adequate protection for intellectual property rights;
9. litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

All mentioned trademarks are legally protected.
Agenda

Welcome
Karl Mahler, Head of Investor Relations

Hemophilia A without inhibitors remains an unmet medical need
Cristin Hubbard, Lifecycle Leader Hemlibra (emicizumab)

HAVEN 3: Phase 3 study of emicizumab prophylaxis in persons with hemophilia A without inhibitors
Johnny Mahlangu, MBBCh, MMed, Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors; additional comments
Gallia Levy, MD, Associate Group Medical Director Hematology

Q&A
Welcome

Karl Mahler
Head of Investor Relations
Hemlibra: Addressing unmet medical needs

**Improved treatment benefit for patients with and without inhibitors**
- Substantially reduced ABR, with zero bleeds in a majority of patients
- Potentially less long-term joint damage and fewer severe / life threatening bleeds
- Prophylactic treatment offers sustained protection
- Non-inhibitor patients did not develop *de novo* FVIII inhibitors

**Reduced treatment burden for patients with and without inhibitors**
- Subcutaneous administration
- Less frequent dosing and flexible dosing options (qw, q2w or q4w dosing)
- Less intensive dosing regime

**Patients prefer Hemlibra**
- Almost all participants in HAVEN 3 and HAVEN 4 preferred Hemlibra over their previous treatment

HAVEN 1: Oldenburg et al. ISTH 2017 (data cutoff: 25 Oct 2016); HAVEN 2: Young et al. ASH 2017 (data cutoff: 8 May 2017); HAVEN 3: Mahlangu et al. WFH 2018 (data cutoff: 15 Sep 2017); HAVEN 4: Pipe et al. WFH 2018
Hemlibra (emicizumab) overview

Cristin Hubbard
Lifecycle Leader Hemlibra
Hemlibra: A bispecific monoclonal antibody designed for hemophilia A

Bridges factors IXa and X, to activate the natural coagulation cascade and restore the blood clotting process

No homology to FVIII

Once weekly subcutaneous injection; less frequent dosing schedules being evaluated
Hemlibra’s Ph3 program addresses all people with hemophilia A

### Data at WFH

**HAVEN 4**: Phase 3 non-inhibitor/inhibitor adults/adolescents
- Every 4 week dosing
- 48 pts enrolled

**HAVEN 3**: Phase 3 non-inhibitor adults/adolescents (≥12 years old)
- Weekly and every other week dosing
- 152 pts enrolled

**HAVEN 2**: Phase 3 inhibitor children (0–11 years old)
- Weekly, every other week, and every 4 week dosing
- 88 pts enrolled

**HAVEN 1**: Phase 3 inhibitor adults/adolescents (≥12 years old)
- Weekly dosing
- 113 pts enrolled

### Approved in US & EU

**Noninterventional study**
- Inhibitor, non-inhibitor, pediatrics
- 221 pts enrolled

**Chugai phase 1/2 studies**
- 18 pts enrolled

Approved in US & EU

Noninterventional study

Chugai phase 1/2 studies
HAVEN 1: Results are statistically robust & clinically meaningful
Primary and all secondary endpoints were met

Annualized bleed rate reduction

<table>
<thead>
<tr>
<th>Interval (weeks)</th>
<th>Arm A</th>
<th>Arm C</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-24</td>
<td>21.4</td>
<td>15.7</td>
</tr>
<tr>
<td>25-48</td>
<td>1</td>
<td>1.8</td>
</tr>
<tr>
<td>49-72</td>
<td>0</td>
<td>0.5</td>
</tr>
</tbody>
</table>

95% reduction: $P < 0.0001$
88% reduction: $P < 0.0001$

Bleed rates over time

Nearly 10 months additional follow-up

Mancuso et al. ASH 2017

1 Negative binomial model (Primary analysis data cutoff: Oct 25, 2016; Updated analysis data cutoff: Sep 8, 2017)
ABR=annualized bleeding rate; BPA=bypassing agent; NIS=non-interventional study; IQR=interquartile range
HAVEN 2: Hemlibra prophylaxis prevents or substantially reduces bleeds in pediatric patients with inhibitors

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>% zero bleeds (95% CI) N=57*</th>
<th>% zero bleeds (95% CI) n=23†</th>
<th>ABR‡ (95% CI) n=23†</th>
<th>Median ABR (IQR) n=23†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated bleeds</td>
<td>94.7 (85.4; 98.9)</td>
<td>87.0 (66.4; 97.2)</td>
<td>0.2 (0.06; 0.62)</td>
<td>0.0 (0.00; 0.00)</td>
</tr>
<tr>
<td>All bleeds</td>
<td>64.9 (51.1; 77.1)</td>
<td>34.8 (16.4; 57.3)</td>
<td>2.9 (1.75; 4.94)</td>
<td>1.5 (0.00; 4.53)</td>
</tr>
<tr>
<td>Treated spontaneous bleeds</td>
<td>98.2 (90.6; 100.0)</td>
<td>95.7 (78.1; 99.9)</td>
<td>0.1 (0.01; 0.47)</td>
<td>0.0 (0.00; 0.00)</td>
</tr>
<tr>
<td>Treated joint bleeds</td>
<td>98.2 (90.6; 100.0)</td>
<td>95.7 (78.1; 99.9)</td>
<td>0.1 (0.01; 0.47)</td>
<td>0.0 (0.00; 0.00)</td>
</tr>
<tr>
<td>Treated target joint bleeds</td>
<td>100 (93.7; 100.0)</td>
<td>100 (85.2; 100.0)</td>
<td>Not estimable</td>
<td>0.0 (0.00; 0.00)</td>
</tr>
</tbody>
</table>

Most patients reported zero treated bleeds; Quality of life improvement seen in pediatric patients on Hemlibra prophylaxis

Young et al. ASH 2017
*Aged <12 years; †Primary efficacy results (ABR analysis) based only on patients aged <12 years on study for ≥12 weeks; ‡Negative binomial regression model.
ABR=annualized bleeding rate; BPA=bypassing agent; IQR=interquartile range
Early launch success of Hemlibra in people with inhibitors
25-30% of people with hemophilia A will develop inhibitors to FVIII

### Launch update

- Hemlibra approved in US (Q4 2017) and EU (Q1 2018)
- US launch demonstrates strong performance driven by patient demand (Q1 2018 US sales of 18.5M CHF); In EU, off to a good start
- CMS has designated Hemlibra as a Part B drug
- In the US, policies with favorable coverage
- Favorable ICER review
- High Hemlibra awareness among inhibitor patients; positive feedback from the community

---

Prophylaxis is established as an optimal treatment regimen in the non-inhibitor segment

Hemophilia A


Non-inhibitor

95%

% prophylaxis:

~60%

~25%

~10%

Hemlibra could drive uptake of prophylactic treatment

Unmet medical need remains in the non-inhibitor segment despite use of prophylaxis

**RWD: Treated bleed category on prophylaxis**

- 0 bleeds: 36%
- 1 bleed: 24%
- 2 bleeds: 17%
- 3-6 bleeds: 13%
- >6 bleeds: 10%

*n=512

**NIS (cohort C)*: Treated bleed category on prophylaxis**

- 0 bleeds: 37%
- 1-3 bleeds: 33%
- >3 bleeds: 30%

*n=49

Potential to improve bleed control and associated disease burden

1Oldenburg et al. EAHAD 2017 (Data from the German and International AHEAD study arm, Year 1); 2Kruse-Jarres R, et al. EAHAD 2018

*NIS Cohort C: adolescent/adult persons with hemophilia A without inhibitors; eligible participants subsequently had the option to enrol in the phase 3 emicizumab HAVEN 3 study (NCT02847637). NIS was conducted between 26 May 2016 and 31 March 2017. Negative binomial regression model; NIS=non-interventional Study; RWD=real world data
HAVEN 3: Phase 3 study of emicizumab prophylaxis in persons with hemophilia A without inhibitors

Johnny Mahlangu, MBBCh, MMed
Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa
Emicizumab prophylaxis administered once-weekly or every two weeks provides effective bleed prevention in persons with haemophilia A without inhibitors – Results from the phase III HAVEN 3 study

Johnny Mahlangu, MBBCh, MMed
Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. These should be reported to the Regulatory authorities in your country according to your national requirements.
**DISCLOSURES FOR:**
**JOHNNY MAHLANGU**

<table>
<thead>
<tr>
<th>Conflict</th>
<th>Disclosure - if conflict of interest exists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant/Research Support</td>
<td>Alnylam, Bayer, Biogen, CSL Behring, F. Hoffmann-La Roche, Novo Nordisk, Sobi</td>
</tr>
<tr>
<td>Consultant/Scientific Board</td>
<td>Amgen, Bayer, Biotest, Biogen, Baxalta, CSL Behring, Catalyst Biosciences, F. Hoffmann-La Roche, Novo Nordisk</td>
</tr>
<tr>
<td>Speaker Bureau</td>
<td>Alnylam, Bayer, Biotest, Novo Nordisk, Pfizer, Sobi, Shire, WFH</td>
</tr>
<tr>
<td>Paid Instructor</td>
<td>No disclosure</td>
</tr>
<tr>
<td>Employee</td>
<td>No disclosure</td>
</tr>
<tr>
<td>Shareholder</td>
<td>No disclosure</td>
</tr>
</tbody>
</table>
HAVEN 3: Background and objectives

- Regular prophylactic intravenous factor VIII (FVIII) infusions are the optimal treatment approach for severe haemophilia A
  - Clinical and subclinical bleeds may occur despite prophylaxis
  - High treatment burden leading to suboptimal care for those unable to adhere
- Therefore, there’s an unmet need for highly effective treatment options with reduced treatment burden
- HAVEN 3 (NCT02847637) was designed to assess the efficacy, safety and pharmacokinetics of subcutaneous emicizumab prophylaxis in persons with haemophilia A without inhibitors
Background: Emicizumab

- Humanised bispecific monoclonal antibody
- Bridges activated FIX (FIXa) and FX to restore function of missing FVIIIa
- No structural homology to FVIII (not expected to induce FVIII inhibitors or be affected by presence of inhibitors)
- Long half-life of ~30 days
- Administered subcutaneously
- Approved in several countries for once-weekly prophylaxis in persons with haemophilia A with inhibitors of all ages

HEMLIBRA (emicizumab-kxwh) [prescribing information]. 2017.
HEMLIBRA (emicizumab) [summary of product characteristics]. 2018.
HAVEN 3: Study design and endpoints

Primary efficacy
- Treated bleed rate (A vs C; B vs C) at minimum 24 weeks

Secondary efficacy
- All bleed rate; joint bleed rate; target joint bleed rate; spontaneous bleed rate; HRQoL/health status
- Bleed rate in prophylaxis Arm D patients vs prior FVIII prophylaxis during NIS

Safety
- Includes incidence of ADAs, TEs, FVIII inhibitors

Emicizumab given subcutaneously and all regimens started with a loading series of 3 mg/kg/week for 4 weeks

**Arm A:** Emicizumab 1.5 mg/kg QW maintenance (n=36)

**Arm B:** Emicizumab 3 mg/kg Q2W maintenance (n=35)

**Arm C:** No prophylaxis (n=18)

**Arm D:** Emicizumab 1.5 mg/kg QW maintenance (n=63)

**Pre-study episodic** FVIII

Persons with severe haemophilia A without inhibitors aged ≥12 years on FVIII treatment

NIS FVIII prophylaxis (n=48)

Pre-study episodic* FVIII

Primary efficacy

Secondary efficacy

Safety

R† 2:2:1

Primary analysis at minimum 24 weeks

Emicizumab

*Prior 24-week bleed rate ≥ 5 for patients receiving episodic FVIII.
†Randomisation stratified based on prior 24-week bleed rate of <9 or ≥9.

**NCT02847637:** phase 3, open-label, multicentre, randomised study; initiated 27 Sept 2016; data cutoff 15 Sept 2017.

ADA, anti-drug antibody; HRQoL, health-related quality of life; QW, once weekly; Q2W, every 2 weeks; R, randomised; TE, thromboembolic event.
HAVEN 3: Demographics and baseline clinical characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Prior episodic treatment</th>
<th>Prior prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Arm A: Emicizumab 1.5 mg/kg QW n=36</td>
<td>Arm B: Emicizumab 3 mg/kg Q2W n=35</td>
</tr>
<tr>
<td>Median (min–max) age, years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years, n (%)</td>
<td>36.5 (19–77)</td>
<td>41.0 (20–65)</td>
</tr>
<tr>
<td>&lt;18</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>≥18</td>
<td>36 (100.0)</td>
<td>35 (100.0)</td>
</tr>
<tr>
<td>&lt;9 bleeds in 24 weeks before study entry, n (%)</td>
<td>9 (25.0)</td>
<td>5 (14.3)</td>
</tr>
<tr>
<td>Target joints, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2 (5.6)</td>
<td>8 (22.9)</td>
</tr>
<tr>
<td>Yes</td>
<td>34 (94.4)</td>
<td>27 (77.1)</td>
</tr>
<tr>
<td>&gt;1 target joint</td>
<td>20/34 (58.8)</td>
<td>22/27 (81.5)</td>
</tr>
</tbody>
</table>
HAVEN 3 primary endpoint: Treated bleeds
Emicizumab QW and Q2W significantly reduced ABR vs no prophylaxis

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Arm A: Emicizumab 1.5 mg/kg QW n=36</th>
<th>Arm B: Emicizumab 3 mg/kg Q2W n=35</th>
<th>Arm C: No prophylaxis n=18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median efficacy period, weeks (min–max)</td>
<td>29.6 (17.3–49.6)</td>
<td>31.3 (7.3–50.6)</td>
<td>24.0 (14.4–25.0)</td>
</tr>
<tr>
<td>ABR, model based* (95% CI)</td>
<td>1.5 (0.9; 2.5)</td>
<td>1.3 (0.8; 2.3)</td>
<td>38.2 (22.9; 63.8)</td>
</tr>
<tr>
<td>Reduction vs Arm C RR, P-value</td>
<td>96% reduction 0.04, P&lt;0.0001</td>
<td>97% reduction 0.03, P&lt;0.0001</td>
<td>—</td>
</tr>
<tr>
<td>Median ABR, calculated (IQR)</td>
<td>0.0 (0.0–2.5)</td>
<td>0.0 (0.0–1.9)</td>
<td>40.4 (25.3–56.7)</td>
</tr>
<tr>
<td>Patients with zero bleeds, % (95% CI)</td>
<td>55.6 (38.1; 72.1)</td>
<td>60.0 (42.1; 76.1)</td>
<td>0.0 (0.0; 18.5)</td>
</tr>
<tr>
<td>Patients with 0–3 bleeds, % (95% CI)</td>
<td>91.7 (77.5; 98.2)</td>
<td>94.3 (80.8; 99.3)</td>
<td>5.6 (0.1; 27.3)</td>
</tr>
</tbody>
</table>

*ABR calculated with negative binomial regression model.

ABR, annualised bleeding rate; IQR, interquartile range; RR, rate ratio.
<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Arm A: Emicizumab 1.5 mg/kg QW n=36</th>
<th>Arm B: Emicizumab 3 mg/kg Q2W n=35</th>
<th>Arm C: No prophylaxis n=18</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All bleeds</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABR, model based* (95% CI)</td>
<td>2.5 (1.6; 3.9)</td>
<td>2.6 (1.6; 4.3)</td>
<td>47.6 (28.5; 79.6)</td>
</tr>
<tr>
<td>% reduction (RR) vs Arm C, P-value</td>
<td>95%, P&lt;0.0001</td>
<td>94%, P&lt;0.0001</td>
<td>—</td>
</tr>
<tr>
<td>% patients with 0 bleeds (95% CI)</td>
<td>50.0 (32.9; 67.1)</td>
<td>40.0 (23.9; 57.9)</td>
<td>0.0 (0.0; 18.5)</td>
</tr>
<tr>
<td><strong>Treated spontaneous bleeds</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABR, model based* (95% CI)</td>
<td>1.0 (0.5; 1.9)</td>
<td>0.3 (0.1; 0.8)</td>
<td>15.6 (7.6; 31.9)</td>
</tr>
<tr>
<td>% reduction (RR) vs Arm C, P-value</td>
<td>94%, P&lt;0.0001</td>
<td>98%, P&lt;0.0001</td>
<td>—</td>
</tr>
<tr>
<td>% patients with 0 bleeds (95% CI)</td>
<td>66.7 (49.0; 81.4)</td>
<td>88.6 (73.3; 96.8)</td>
<td>22.2 (6.4; 47.6)</td>
</tr>
<tr>
<td><strong>Treated joint bleeds</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABR, model based* (95% CI)</td>
<td>1.1 (0.6; 1.9)</td>
<td>0.9 (0.4; 1.7)</td>
<td>26.5 (14.7; 47.8)</td>
</tr>
<tr>
<td>% reduction (RR) vs Arm C, P-value</td>
<td>96%, P&lt;0.0001</td>
<td>97%, P&lt;0.0001</td>
<td>—</td>
</tr>
<tr>
<td>% patients with 0 bleeds (95% CI)</td>
<td>58.3 (40.8; 74.5)</td>
<td>74.3 (56.7; 87.5)</td>
<td>0.0 (0.0; 18.5)</td>
</tr>
<tr>
<td><strong>Treated target joint bleeds</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABR, model based* (95% CI)</td>
<td>0.6 (0.3; 1.4)</td>
<td>0.7 (0.3; 1.6)</td>
<td>13.0 (5.2; 32.3)</td>
</tr>
<tr>
<td>% reduction (RR) vs Arm C, P-value</td>
<td>95%, P&lt;0.0001</td>
<td>95%, P&lt;0.0001</td>
<td>—</td>
</tr>
<tr>
<td>% patients with 0 bleeds (95% CI)</td>
<td>69.4 (51.9; 83.7)</td>
<td>77.1 (59.9; 89.6)</td>
<td>27.8 (9.7; 53.5)</td>
</tr>
</tbody>
</table>

*ABR calculated with negative binomial regression model.
In Arm D (n=63), 48 patients were followed prospectively in the NIS on FVIII prophylaxis and included in an intraindividual analysis.

The NIS prospectively collected data on bleeds and FVIII administration, using the same methodology as in HAVEN 3.

The availability of granular data enabled paired analyses using identical definitions and methodologies.

Investigators attested that each patient received adequate prophylaxis.

Intraindividual comparison controls for interpatient variability (e.g. bleeding characteristics, risk factors for bleeds, and patient recognition of bleeds).
HAVEN 3: Intraindividual comparison of treated bleeds
Emicizumab significantly reduced ABR vs prior FVIII prophylaxis

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Arm D: Emicizumab 1.5 mg/kg QW n=48*</th>
<th>NIS: FVIII prophylaxis n=48</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of efficacy period, median (min-max), weeks</td>
<td>33.7 (20.1–48.6)</td>
<td>30.1 (5.0–45.1)</td>
</tr>
<tr>
<td>ABR, model based (95% CI)†</td>
<td>1.5 (1.0; 2.3)</td>
<td>4.8 (3.2; 7.1)</td>
</tr>
<tr>
<td>Reduction vs NIS FVIII RR, P-value</td>
<td><strong>68% reduction</strong> 0.32, P&lt;0.0001</td>
<td>—</td>
</tr>
<tr>
<td>Median ABR, calculated (IQR)</td>
<td>0.0 (0.0–2.1)</td>
<td>1.8 (0.0–7.6)</td>
</tr>
<tr>
<td>Patients with zero bleeds, % (95% CI)</td>
<td>54.2 (39.2; 68.6)</td>
<td>39.6 (25.8; 54.7)</td>
</tr>
<tr>
<td>Patients with 0–3 bleeds, % (95% CI)</td>
<td>91.7 (80.0; 97.7)</td>
<td>72.9 (58.2; 84.7)</td>
</tr>
</tbody>
</table>

- For all patients in Arm D (n=63), ABR (95% CI) was 1.6 (1.1; 2.4) and 55.6% (95% CI, 42.5; 68.1) had zero bleeds

*Data from 48 patients in Arm D who participated in the NIS shown.
†ABR calculated with negative binomial regression model.
FVIII prophylactic therapies: Results of phase 3 studies

- Measures for efficacy endpoints not consistently reported across all FVIII studies and some studies included subgroup analyses
  - Advate,¹ NovoEight,² Nuwiq,³ Kovaltry,⁴ Afstyla,⁵ Eloctate,⁶ Adynovate,⁷ Bay 94-9027⁸ and N8-GP⁹

*Octocog alfa, 3x/week; percentage represents subgroup with observation of 1-year treatment period.

1. Advate USPI; Valentino et al. 2012.
3. Nuwiq USPI; Lissitchkov et al. 2015.
5. Afstyla USPI; Mahlangu et al. 2016.
7. Adynovate USPI; Konkle et al. 2015.
Proportion of patients with target joints* was reduced with emicizumab.

Incidence of target joints in a post-hoc analysis

*Target joints are defined as a major joint into which ≥3 bleeds occur over a 24-week period. At study entry, the presence of target joints based on bleeds in the 24 weeks before enrolment was recorded. In a post-hoc analysis, target joints were identified within any 24-week period during emicizumab treatment (or the initial period for patients with <24 weeks of treatment) before up-titration (if applicable). Arm C patients after switchover to emicizumab were excluded from this analysis due to the limited follow-up period.
HAVEN 3: Haem-A-QoL Physical Health domain score
Emicizumab resulted in numerical improvement

<table>
<thead>
<tr>
<th></th>
<th>Arm A: Emicizumab 1.5 mg/kg QW n=36</th>
<th>Arm B: Emicizumab 3 mg/kg Q2W n=35</th>
<th>Arm C: No prophylaxis n=17*</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Physical Health domain score at Week 25</th>
<th>34</th>
<th>29</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted mean difference (95% CI) vs Arm C</td>
<td>12.5 (−2.0; 27.0)</td>
<td>16.0 (1.2; 30.8)</td>
<td>—</td>
</tr>
<tr>
<td>P-value</td>
<td>0.089</td>
<td>0.035</td>
<td>—</td>
</tr>
</tbody>
</table>

- Since the comparison of Haem-A-QoL between Arms A and C is not statistically significant, the comparison of Arms B and C is not considered statistically significant due to the order of endpoints in the hierarchical testing framework.

*Haem-A-QoL, Haemophilia-Specific Quality of Life Questionnaire for Adults not administered to adolescents (n=1).
Exploratory efficacy endpoint assessed patient preference using the EmiPref survey
- Completed by 95/134 (70.9%) eligible patients (Arms A, B and D)

Of all survey responders, 93.7% (95% CI, 86.8; 97.7) preferred emicizumab
- Importantly, 45/46 (97.8%) patients in Arm D favoured emicizumab over FVIII prophylaxis

### Which of the treatments would you prefer to take as the treatment for your haemophilia? (Mark ONLY one response)

- Prefer my old haemophilia treatment (IV)
- Prefer Emicizumab treatment (SC)
- Have no preference
HAVEN 3: Safety summary
Favourable safety profile observed with emicizumab

<table>
<thead>
<tr>
<th>Event (MedDRA Preferred Term)</th>
<th>Arm A: Emicizumab 1.5 mg/kg QW n=36</th>
<th>Arm B: Emicizumab 3 mg/kg Q2W n=35</th>
<th>Arm C: Emicizumab 3 mg/kg Q2W n=16*</th>
<th>Arm D: Emicizumab 1.5 mg/kg QW n=63</th>
<th>Total N=150</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of AEs, n</td>
<td>143</td>
<td>145</td>
<td>19</td>
<td>236</td>
<td>543</td>
</tr>
<tr>
<td>Total patients ≥1 AE, n (%)</td>
<td>34 (94.4)</td>
<td>30 (85.7)</td>
<td>8 (50.0)</td>
<td>55 (87.3)</td>
<td>127 (84.7)</td>
</tr>
<tr>
<td>Number of serious AEs</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>Emicizumab related serious AEs</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Selected AEs occurring in ≥5% of all patients, n (%)†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection-site reaction‡</td>
<td>9 (25.0)</td>
<td>7 (20.0)</td>
<td>2 (12.5)</td>
<td>20 (31.7)</td>
<td>38 (25.3)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>4 (11.1)</td>
<td>4 (11.4)</td>
<td>0</td>
<td>8 (12.7)</td>
<td>16 (10.7)</td>
</tr>
<tr>
<td>Patients with AE leading to withdrawal, n (%)</td>
<td>0</td>
<td>1 (2.9)</td>
<td>0</td>
<td>0</td>
<td>1 (0.7)</td>
</tr>
</tbody>
</table>

- 1 patient in Arm B discontinued due to multiple mild AEs (insomnia, hair loss, nightmare, lethargy, depressed mood, headache and pruritus); 2 patients were lost to follow-up (Arms A and C, 1 patient each)
- Of 215 events of co-exposure to FVIII and emicizumab in 64 patients, 43 included an average FVIII dose ≥50 IU/kg/24 hours, of which 8 events lasted >24 hours; co-exposure to emicizumab and FVIII was not related to serious AEs, TMA or TEs
- No deaths
- No serious AE was associated with emicizumab per investigator assessment
- No ADAs detected; no patients on emicizumab developed de novo FVIII inhibitors

*Data represent period of emicizumab prophylaxis only; at the clinical cutoff date, 1 patient was lost to follow-up and another was waiting to start emicizumab.
†Other AEs in ≥5% of all patients: arthralgia (19%), nasopharyngitis (12%), headache (11%), and influenza (6%).
‡Grades 1–2 AE. 1 additional patient in Arm D (and total column) reported an “injection site erythema” not “injection site reaction” as the Preferred Term.
HAVEN 3: Emicizumab pharmacokinetics
QW or Q2W achieve sustained effective trough concentrations

Emicizumab trough concentrations were consistent with a T½ of ~30 days

Arm C data represents patients who switched to emicizumab prophylaxis after completing ≥24 weeks on study.

HAVEN 3: Conclusions

- Emicizumab prophylaxis QW or Q2W achieved highly effective prophylaxis of bleeds in adults/adolescents with haemophilia A without inhibitors
- Notably, an intraindividual comparison demonstrated superiority of bleed rate with emicizumab (QW) over prior FVIII prophylaxis
- Nearly all patients preferred emicizumab over their prior haemophilia treatment
- A favourable safety profile for emicizumab was observed in HAVEN 3
  - No TE or TMA, and no unexpected safety signal
  - No related serious AEs
  - No ADAs or de novo FVIII inhibitors detected
- Subcutaneous emicizumab prophylaxis can provide a highly efficacious and flexible treatment option, with reduced burden for persons with haemophilia A
Co-authors

- Johannes Oldenburg: Universitätsklinikum Bonn, Bonn, Germany
- Ido Paz-Priel: Genentech Inc., South San Francisco, CA, USA
- Claude Negrier: Louis Pradel University Hospital, Lyon, France
- Markus Niggli: F. Hoffmann-La Roche Ltd., Basel, Switzerland
- Maria Elisa Mancuso: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy
- Christophe Schmitt: F. Hoffmann-La Roche Ltd., Basel, Switzerland
- Victor Jiménez-Yuste: Hospital Universitario La Paz, Autónoma University, Madrid, Spain
- Christine Kempton: Department of Hematology and Medical Oncology, HoG Inc., Emory School of Medicine, Atlanta, GA, USA
- Christophe Dhalluin: F. Hoffmann-La Roche Ltd., Basel, Switzerland
- Michael Callaghan: Children’s Hospital of Michigan, Detroit, MI, USA
- Willem Bujan: Instituto Costarricense de Investigaciones Científicas, San José, Costa Rica
- Midori Shima: Department of Pediatrics, Nara Medical University, Kashihara, Japan
- Joanne I. Adamkewicz: Genentech Inc., South San Francisco, CA, USA
- Elina Asikanius: F. Hoffmann-La Roche Ltd., Basel, Switzerland
- Gallia G. Levy: Genentech Inc., South San Francisco, CA, USA
- Rebecca Kruse-Jarres: Washington Center for Bleeding Disorders at Bloodworks Northwest, Seattle, WA, USA
Acknowledgements

The authors would like to thank:

- Study participants and their families
- Study investigators and site personnel

- Ross Baker (Australia), Willen Bujan (Costa Rica), Michael Callaghan (United States), Giancarlo Castaman (Italy), Chia-Yau Chang (Taiwan), Pratima Chowdary (United Kingdom), Peter Collins (United Kingdom), Laurent Frenzel (France), Katsuyuki Fukutake (Japan), Andrezej Hellmann (Poland), Mark Hus (Poland), Toshihiro Ito (Japan), Victor Jiménez-Yuste (Spain), Christine Kempton (United States), Craig Kessler (United States), Jin Seok Kim (Republic of Korea), Rebecca Kruse-Jarres (United States), Thierry Lambert (France), Johnny Mahlangu (South Africa), Tadashi Matsushita (Japan), Catherine McGuinn (United States), Simon McRae (Australia), Claude Negrier (France), Yasuharu Nishida (Japan), Ramiro Núñez (Spain), Niamh O. Connell (Ireland), Johannes Oldenburg (Germany), Aric Parnes (United States), Doris Quon (United States), Anita Rajasekhar (United States), Elena Santagostino (Italy), Ming-Ching Shen (Taiwan), Midori Shima (Japan), Takashi Suzuki (Japan), Masashi Taki (Japan), Huyen Tran (Australia), Jiaan-Der Wang (Taiwan), Jerzy Windyga (Poland), Tomasz Wozny (Poland)

- This study was co-sponsored by F. Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co., Ltd.

- Writing assistance was provided by Daniella Babu, PhD, of Envision Pharma Group, and funded by F. Hoffmann-La Roche Ltd.
HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors; additional comments

Gallia Levy, MD, PhD
Global Development Leader Hemlibra
HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors

Additional comments
Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with haemophilia A with and without inhibitors – Results from the phase 3 HAVEN 4 study

Steven Pipe, MD
University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, MI, USA

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. These should be reported to the Regulatory authorities in your country according to your national requirements.
DISCLOSURES FOR:
STEVEN PIPE

<table>
<thead>
<tr>
<th>Conflict</th>
<th>Disclosure - if conflict of interest exists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Support</td>
<td>Shire</td>
</tr>
<tr>
<td>Director, Officer, Employee</td>
<td>MASAC-NHF</td>
</tr>
<tr>
<td>Shareholder</td>
<td>No disclosure</td>
</tr>
<tr>
<td>Honoraria</td>
<td>No disclosure</td>
</tr>
<tr>
<td>Advisory Committee</td>
<td>No disclosure</td>
</tr>
<tr>
<td>Consultant</td>
<td>Alnylam, ApcinteX, Bayer, BioMarin, Bioverativ, CSL Behring, F. Hoffmann La-Roche, Novo Nordisk, Pfizer, Shire, uniQure</td>
</tr>
</tbody>
</table>
Background: Emicizumab

- Humanised bispecific monoclonal antibody
- Bridges activated factor IX (FIXa) and FX to restore function of missing FVIIIa
- No structural homology to FVIII (not expected to induce FVIII inhibitors or be affected by presence of FVIII inhibitors)
- Long half-life of ~30 days
- Administered subcutaneously
- Approved in several countries for once-weekly prophylaxis in persons with haemophilia A with inhibitors of all ages
# Emicizumab clinical trials

<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Population</th>
<th>ABR, treated bleeds: emicizumab prophylaxis vs no prophylaxis</th>
<th>% patients with zero treated bleeds</th>
<th>ABR, treated bleeds: emicizumab prophylaxis vs prior prophylaxis in NIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAVEN 1</td>
<td>PwHA ≥12 years with FVIII inhibitors</td>
<td>▪ 87% reduction (QW)*</td>
<td>▪ 63% (QW), 6% (no prophylaxis)</td>
<td>▪ 79% reduction with emicizumab QW vs prior BPA prophylaxis</td>
</tr>
<tr>
<td>(NCT02622321)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAVEN 2</td>
<td>PwHA &lt;12 years with FVIII inhibitors</td>
<td>▪ N/A (no comparator)</td>
<td>▪ 87% (QW)</td>
<td>▪ 99% reduction with emicizumab QW vs prior BPA prophylaxis</td>
</tr>
<tr>
<td>(NCT02795767)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAVEN 3</td>
<td>PwHA ≥12 years without FVIII inhibitors</td>
<td>▪ 96% reduction (QW)</td>
<td>▪ 56% (QW), 60% (Q2W), 0% (no prophylaxis)</td>
<td>▪ 68% reduction with emicizumab QW vs prior FVIII prophylaxis</td>
</tr>
<tr>
<td>(NCT02847637)</td>
<td></td>
<td>▪ 97% reduction (Q2W)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAVEN 4</td>
<td>PwHA ≥12 years with or without FVIII inhibitors</td>
<td>▪ Primary analyses evaluating emicizumab Q4W prophylaxis on bleeding rate, safety, PK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(NCT03020160)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Improved bleeding rate observed in subsequent 24-week periods beyond initial 24-weeks.


ABR, annualized bleeding rate; BPA, bypassing agent; PwHA, persons with Haemophilia A; PK, pharmacokinetics; Q2W, every 2 weeks; Q4W, every 4 weeks; QW, once weekly.
PK and efficacy modelling for different emicizumab dosing regimens

- All 3 regimens were expected to achieve clinically efficacious concentrations and provide similar efficacy.
- All dosing regimens begin with loading period of 3 mg/kg/week for 4 weeks, followed by maintenance dose as indicated.
HAVEN 4: Study design

**PK run-in cohort (n=7)**
PwHA aged ≥12 years (prior episodic treatment); emicizumab 6 mg/kg Q4W* for ≥24 weeks

**Expansion cohort (n=41)**
**Loading dose:** Emicizumab 3 mg/kg QW for 4 weeks, followed by **Maintenance dose:** Emicizumab 6 mg/kg Q4W for ≥24 weeks

**Analyses**
PK and safety (last patient at Week 6 of treatment)

**Analyses**
Efficacy, safety, PK/PD

**Expansion cohort:**
- Severe haemophilia A with or without inhibitors
- Documented episodic or prophylactic treatment with FVIII replacement or BPAs for ≥24 weeks before study entry
- Median (range) efficacy period: 25.6 (24.1–29.4) weeks


*Dosing regimens different in PK run-in and expansion cohorts.
HAVEN 4
Expansion cohort: Study objectives

- **Efficacy**
  - Treated bleed rate, all bleed rate, joint bleed rate, target joint bleed rate, spontaneous bleed rate
  - Health-related quality of life/health status and functional outcomes (e.g. absences), preference (EmiPref)

- **Safety**
  - Incidence and severity of AEs, including thromboembolic events, severe hypersensitivity, injection-site reactions and laboratory abnormalities
  - Drug discontinuation
  - Incidence of ADAs and *de novo* FVIII inhibitors (in PwHA without inhibitors)

- **Pharmacokinetic**
  - Characterization of the PK profile after multiple Q4W subcutaneous doses of 6 mg/kg emicizumab

- **Exploratory**
  - Biomarkers (e.g. aPTT, thrombin generation assay, FVIII activity)

ADA, anti-drug antibodies, AE, adverse event; aPTT, activated partial thromboplastin time.
# HAVEN 4
Demographics and baseline characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Emicizumab 6 mg/kg Q4W N=41</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male, n (%)</strong></td>
<td>41 (100.0)</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
</tr>
<tr>
<td>Median (min–max), years</td>
<td></td>
</tr>
<tr>
<td>≥18 years, n (%)</td>
<td></td>
</tr>
<tr>
<td>≥18 years, n (%)</td>
<td>39 (14–68)</td>
</tr>
<tr>
<td>92.7%</td>
<td></td>
</tr>
<tr>
<td><strong>Severe haemophilia A, n (%)</strong></td>
<td>40 (97.6)</td>
</tr>
<tr>
<td><strong>Bleeds in 24 weeks before study entry, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;9</td>
<td>28 (68.3)</td>
</tr>
<tr>
<td>≥9</td>
<td>13 (31.7)</td>
</tr>
<tr>
<td><strong>Target joints, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>16 (39.0)</td>
</tr>
<tr>
<td>Yes</td>
<td>25 (61.0)</td>
</tr>
<tr>
<td><strong>FVIII inhibitor present at study entry, n (%)</strong></td>
<td>5 (12.2)</td>
</tr>
</tbody>
</table>

*Includes 1 patient with mild haemophilia and inhibitors (32 BU/mL), and <1% FVIII activity at study entry.
HAVEN 4
Effective bleed control achieved with emicizumab Q4W

- Median (range) efficacy period, 25.6 (24.1–29.4) weeks
- Majority (38/51 [74.5%]) of treated bleeds were traumatic

<table>
<thead>
<tr>
<th>Bleeds n=41 pts</th>
<th>ABR, model based (95% CI)*</th>
<th>Median ABR, calculated (IQR)</th>
<th>Zero bleeds, % pts (95% CI)</th>
<th>0–3 bleeds, % pts (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated bleeds</td>
<td>2.4 (1.4; 4.3)</td>
<td>0.0 (0.0; 2.1)</td>
<td>56.1 (39.7; 71.5)</td>
<td>90.2 (76.9; 97.3)</td>
</tr>
<tr>
<td>All bleeds</td>
<td>4.5 (3.1; 6.6)</td>
<td>2.1 (0.0; 5.9)</td>
<td>29.3 (16.1; 45.5)</td>
<td>80.5 (65.1; 91.2)</td>
</tr>
<tr>
<td>Treated spontaneous bleeds</td>
<td>0.6 (0.3; 1.5)</td>
<td>0.0 (0.0; 0.0)</td>
<td>82.9 (67.9; 92.8)</td>
<td>97.6 (87.1; 99.9)</td>
</tr>
<tr>
<td>Treated joint bleeds</td>
<td>1.7 (0.8; 3.7)</td>
<td>0.0 (0.0; 1.9)</td>
<td>70.7 (54.5; 83.9)</td>
<td>95.1 (83.5; 99.4)</td>
</tr>
<tr>
<td>Treated target joint bleeds</td>
<td>1.0 (0.3; 3.3)</td>
<td>0.0 (0.0; 0.0)</td>
<td>85.4 (70.8; 94.4)</td>
<td>97.6 (87.1; 99.9)</td>
</tr>
</tbody>
</table>

*ABR calculated with negative binomial regression model.

IQR, interquartile range; pt, patient.
HAVEN 4 Haem-A-QoL Physical Health domain score
Emicizumab resulted in a numerical improvement

<table>
<thead>
<tr>
<th></th>
<th>Emicizumab 6 mg/kg Q4W</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
</tr>
<tr>
<td>Patients, n</td>
<td>38</td>
</tr>
<tr>
<td>Physical Health domain score, mean (SD)</td>
<td>47.0 (25.1)</td>
</tr>
<tr>
<td>Change from baseline, mean (95% CI)</td>
<td>–</td>
</tr>
</tbody>
</table>

- Change from baseline in the Physical Health domain score for meaningful improvements: ≥10 points (responder threshold)
HAVEN 4: Patient preference
All patients preferred emicizumab

<table>
<thead>
<tr>
<th>Which of the treatments would you prefer to take as the treatment for your haemophilia? (Mark ONLY one response)</th>
</tr>
</thead>
<tbody>
<tr>
<td>◦ Prefer my old haemophilia treatment (IV)</td>
</tr>
<tr>
<td>◦ Prefer Emicizumab treatment (SC)</td>
</tr>
<tr>
<td>◦ Have no preference</td>
</tr>
</tbody>
</table>

- EmiPref survey was completed by all 41 (100%) eligible patients
- 100% (95% CI, 91.4; 100.0) of patients preferred emicizumab

IV, intravenous; SC, subcutaneous.
HAVEN 1 – 4: Emicizumab pharmacokinetics
Trough concentrations by dosing regimen (QW, Q2W and Q4W)

- Clinically efficacious concentrations obtained with all 3 dosing regimens (consistent with PK model predictions)
- For Q4W, emicizumab mean trough concentrations were maintained at ~41 µg/mL from Week 13 to Week 25

HAVEN 4
Favourable safety profile observed with emicizumab

<table>
<thead>
<tr>
<th></th>
<th>Emicizumab 6 mg/kg Q4W N=41</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of AEs</td>
<td>148</td>
</tr>
<tr>
<td>Total patients ≥1 AE, n (%)</td>
<td>30 (73.2)</td>
</tr>
<tr>
<td>Serious AE*</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Grade ≥3 AE</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Related AE</td>
<td>12 (29.3)</td>
</tr>
<tr>
<td>Local injection-site reaction</td>
<td>9 (22.0)</td>
</tr>
<tr>
<td>AEs of special interest, n (%)</td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>0</td>
</tr>
<tr>
<td>TE/TMA</td>
<td>0</td>
</tr>
</tbody>
</table>

- 73.2% of patients experienced ≥1 AE
- Only 1 serious (Grade ≥3) AE of rhabdomyolysis unrelated to emicizumab
- Injection-site reaction was the most common emicizumab-related AE (22.0%)
- No AEs led to emicizumab discontinuation or withdrawal
- No TEs, TMAs or hypersensitivity reactions
- No ADAs detected; no patients developed de novo FVIII inhibitors


*1 serious AE in the PK run-in cohort: grade 3 hypertension in patient with medical history of hypertension; unrelated to emicizumab treatment.
HAVEN 4
Conclusions

- Emicizumab Q4W was safe and efficacious in PwHA ≥12 years with and without inhibitors
- Efficacy results were consistent across bleed-related endpoints and with other HAVEN studies
- Emicizumab was associated with a numerical improvement in Haem-A-QoL Physical Health domain score
- All patients preferred emicizumab over their prior haemophilia treatment
- Pharmacokinetic profiles support the efficacy data and were consistent with predictions
- Emicizumab showed a favourable safety profile with no TEs or TMAs
  - Most common AEs consistent with prior experience
  - Incidence of injection-site reaction in line with other HAVEN studies and mainly mild to moderate
  - No ADAs or de novo FVIII inhibitors detected

Co-authors

- Victor Jiménez-Yuste: Hospital Universitario La Paz, Autónoma University, Madrid, Spain
- Amy Shapiro: Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA
- Nigel Key: University of North Carolina, Chapel Hill, NC, USA
- Maria Podolak-Dawidziak: Medical University Department of Hematology, Wroclaw, Poland
- Cedric Hermans: Cliniques Universitaires St-Luc, Brussels, Belgium
- Kathelijne Peerlinck: UZ Leuven Gasthuisberg, Leuven, Belgium
- Michaela Lehle, Sammy Chebon, Agnes Portron and Nives Selak Bienz: F. Hoffmann-La Roche Ltd., Basel, Switzerland
- Gallia G. Levy: Genentech Inc., South San Francisco, CA, USA
- Midori Shima: Nara Medical University, Department of Pediatrics, Kashihara, Japan
Acknowledgements

- The authors would like to thank:
  - Study participants and their families
  - Study investigators and site personnel:
    - Santiago Bonanad Boix (Spain), Katsuyuki Fukutake (Japan), Adam Giermasz (USA), Cedric Hermans (Belgium), Akira Ishiguro (Japan), Victor Jiménez-Yuste (Spain), Nigel Key (USA), Simon McRae (Australia), Ramiro Núñez (Spain), Kathelijne Peerlinck (Belgium), Steven Pipe (USA), Maria Podolak-Dawidziak (Poland), John Rowell (Australia), Amy Shapiro (USA), Midori Shima (Japan), Takanori Teshima (Japan), Jerzy Windyga (Poland)
    - This study was co-sponsored by F. Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co., Ltd.
- Writing assistance was provided by Daniella Babu, PhD, of Envision Pharma Group, and funded by F. Hoffmann-La Roche Ltd.
HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors

Additional comments
Pivotal trials demonstrate robust safety profile of Hemlibra
No new safety events of concern

<table>
<thead>
<tr>
<th>Event</th>
<th>HAVEN 1 N=112</th>
<th>HAVEN 2 N=60</th>
<th>HAVEN 3 N=150</th>
<th>HAVEN 4 N=41</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of AEs, n</td>
<td>457</td>
<td>201</td>
<td>543</td>
<td>148</td>
</tr>
<tr>
<td>Total patients ≥1 AE, n (%)</td>
<td>96 (85.7)</td>
<td>40 (66.7)</td>
<td>127 (84.7)</td>
<td>30 (73.2)</td>
</tr>
<tr>
<td>Serious AE, n (%)</td>
<td>19 (17.0)</td>
<td>6 (10.0)</td>
<td>14</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>TMA</td>
<td>3 (2.7)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TE</td>
<td>2 (1.8)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fatal AEs, n (%)(^1)</td>
<td>1 (0.9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AEs leading to withdrawal, n (%)</td>
<td>3 (2.7)</td>
<td>0</td>
<td>1 (0.7)</td>
<td>0</td>
</tr>
<tr>
<td>Local injection-site reaction, n (%)</td>
<td>16 (14.3)</td>
<td>10 (16.7)</td>
<td>38 (25.3)</td>
<td>9 (22.0)</td>
</tr>
</tbody>
</table>

No TMA/TE events reported in persons without inhibitors on Hemlibra;
In persons with inhibitors, BPA treatment guidance is in place to treat breakthrough bleeds in patients on Hemlibra.

\(^1\)HAVEN 1: Mancuso et al. ASH 2017 (data cutoff: 8 Sep 2017); \(^2\)HAVEN 2: Young et al. ASH 2017 (data cutoff: 8 May 2017); \(^3\)HAVEN 3: Mahlangu et al. WFH 2018 (data cutoff: 15 Sep 2017); \(^4\)HAVEN 4: Pipe et al. WFH 2018 (data cutoff: 15 Dec 2017; Efficacy period for interim analysis: 25.8 weeks (24.1-29.4))

AE=adverse event; TMA=thrombotic microangiopathy; TE=thromboembolic event
Randomized trials vs. intra-individual comparison

Intra-individual comparison is a robust trial design in hemophilia A

### Randomized trial

- **i.e. Oncology:**
  - Disease progression
  - 1L
  - 2L
  - Treatment group
  - Control group

### Intra-individual comparison

- **i.e. Hemophilia A:**
  - Disease progression
  - Linear course of disease
  - Treatment 1
  - Treatment 2

#### Randomized trial

- Gold standard and suitable for both progressive and non-progressive diseases
- Aims to equalize distribution of known and unknown prognostic factors to each arm
- Allows for placebo control in cases where this is feasible and acceptable
- Might not fully balance all prognostic factors; does not tease out impact of one therapy vs another at a patient level

#### Intra-individual comparison

- Feasible only for non-progressive disease
- Known and unknown prognostic factors automatically balanced; controls for intra-patient variability
- Can measure impact at group level and patient level; important insights on how therapies differ in the same person
HAVEN 3 Arm D: Hemlibra prophylaxis showed superior efficacy as demonstrated by a significant reduction in treated bleeds

**Treated bleeds - Hemlibra QW vs FVIII prophylaxis**

- **ABR (95% CI)**
  - NIS: FVIII prophylaxis: 4.8 (3.2; 7.1)
  - Arm D*: QW: 1.5 (1.0; 2.3)

- **68% reduction**
  - p<0.0001

**Patients with 0-3 bleeds**

- **% patient with 0-3 bleeds**
  - NIS: FVIII prophylaxis: 72.9 (58.2; 84.7)
  - Arm D*: QW: 91.7 (80.0; 97.7)

Hemlibra prophylaxis resulted in a statistically significant reduction in treated bleeds of 68% compared to previous treatment with FVIII prophylaxis

Mahlangu et al. WFH 2018; data cutoff 15 Sept 2017

*Data from 48 patients in Arm D who participated in the NIS shown.

ABR=annualised bleed rate; CI=confidence interval; F=factor; NIS=non-interventional study; QW=once-weekly administration; Q2W= administered every 2 weeks
# FVIII prophylactic therapies: Results of Phase 3 studies

<table>
<thead>
<tr>
<th>Brand name</th>
<th>Frequency of IV administration</th>
<th>N</th>
<th>Mean ABR (95% CI or ± SD)</th>
<th>Median ABR (IQR or range)</th>
<th>% patients zero bleeds</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NIS: Standard or extended half-life FVIII</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard half-life FVIII</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advate®</td>
<td>Q2d</td>
<td>30 (std)</td>
<td>1.6 (± 1.2)</td>
<td>1 (2.1) †</td>
<td>42%</td>
<td>Advate USPI, Valentino et al. 2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>23 (PK)</td>
<td>1.9 (± 1.1)</td>
<td>1 (4.1) †</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>NovoEight®</td>
<td>3x/wk or Q2d</td>
<td>213</td>
<td>6.5 (5.3, 8)</td>
<td>3.1 (7.3) †</td>
<td>50%</td>
<td>NovoEight USPI, Lentz et al. 2013</td>
</tr>
<tr>
<td>Nuwiq®</td>
<td>3x/wk or Q2d</td>
<td>32 (adult) 59 (peds)</td>
<td>2.3 (± 3.7) 4.1 (± 5.2)</td>
<td>0.9 (0–14.7) 1.9 (0–20.7)</td>
<td>33.9%</td>
<td>Nuwiq USPI, Lisitschekov et al. 2015</td>
</tr>
<tr>
<td>Kovaltry®</td>
<td>2x/wk</td>
<td>18</td>
<td>3.8 (± 5.2)</td>
<td>1 (0, 8)</td>
<td>37.5% †</td>
<td>Kovaltry USPI, Saxena et al. 2016, Kavakli et al. 2015</td>
</tr>
<tr>
<td></td>
<td>3x/wk</td>
<td>44</td>
<td>4.9 (± 6.8)</td>
<td>2 (0, 4.9)</td>
<td>25.8%</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>2x/wk</td>
<td>28</td>
<td>4 (0.8)</td>
<td>28.6%</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3x/wk</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Afstyla®</td>
<td>2–3x/wk</td>
<td>146</td>
<td>3.1 (± 5.1)</td>
<td>1.1 (0, 4.2)</td>
<td>43%</td>
<td>Afstyla USPI, Mahlangu et al. 2016</td>
</tr>
<tr>
<td>Extended half-life FVIII</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eloctate®</td>
<td>Q3-5d</td>
<td>117</td>
<td>2.9 (2.3, 3.7)</td>
<td>1.6 (0, 4.7)</td>
<td>45%</td>
<td>Eloctate USPI, Mahlangu et al. 2014</td>
</tr>
<tr>
<td>Adynovate®</td>
<td>2x/wk</td>
<td>120 (ITT)</td>
<td>4.7 (± 8.6)</td>
<td>1.9 (0, 5.8)</td>
<td>38%</td>
<td>Adynovate USPI, Konkle et al. 2015</td>
</tr>
<tr>
<td>Bay 94-9027*</td>
<td>Q5d</td>
<td>43</td>
<td>–</td>
<td>1.9 (0, 4.2)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>QW</td>
<td>43</td>
<td>–</td>
<td>3.9 (0, 6.5)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>2x/wk</td>
<td>11</td>
<td>–</td>
<td>1.9 (0, 5.2)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>2x/wk</td>
<td>13</td>
<td>–</td>
<td>4.1 (2, 10.6)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>N8-GP*</td>
<td>Q4d</td>
<td>175</td>
<td>3.7 (2.9; 4.7)</td>
<td>1.3 (0, 4.6)</td>
<td>40%</td>
<td>Giangrande et al. 2017</td>
</tr>
</tbody>
</table>

Cross-trial comparisons or claims of inferiority or superiority are not appropriate.

*Not an approved therapy.

1. IQR = difference between 75th percentile (3rd quartile) and 25th percentile (1st quartile).

2. Of a subgroup of 16 patients with observation of one-year treatment period.

ABR=annualized bleeding rate; F=factor; std/PK=standard (20–40 IU kg⁻¹ every other day) or pharmacokinetic (PK)-tailored (20–80 IU kg⁻¹ every third day) prophylaxis; ITT=intent to treat;

Q2d=every two days; Q4d=every 4 days; Q5d=every 5 days; r=recombinant

**Estimated ABR by negative binomial model
Consistency of results from HAVEN studies demonstrate dosing flexibility with Hemlibra

<table>
<thead>
<tr>
<th>Primary endpoint: Treated bleeds</th>
<th>HAVEN 1 Arm A N=35, qw</th>
<th>HAVEN 2 N=23, qw</th>
<th>HAVEN 3 Arm A N=36, qw</th>
<th>HAVEN 3 Arm B N=35, q2w</th>
<th>HAVEN 4 N=41, q4w</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABR, model based (95% CI)*</td>
<td>2.9 (1.7; 5.0)</td>
<td>0.2 (0.06; 0.62)</td>
<td>1.5 (0.9; 2.5)</td>
<td>1.3 (0.8; 2.3)</td>
<td>2.4 (1.4; 4.3)</td>
</tr>
<tr>
<td>Reduction RR, P-value</td>
<td>87% reduction, 0.13, p&lt;0.001 (vs Arm B)</td>
<td>NA</td>
<td>96% reduction, 0.04, p&lt;0.0001 (vs Arm C)</td>
<td>97% reduction, 0.03, p&lt;0.0001 (vs Arm C)</td>
<td>NA</td>
</tr>
<tr>
<td>Median ABR, calculated (IQR)</td>
<td>0.0 (0.0; 3.7)</td>
<td>0.0 (0.00; 0.00)</td>
<td>0.0 (0.0; 2.5)</td>
<td>0.0 (0.0; 1.9)</td>
<td>0.0 (0.0; 2.1)</td>
</tr>
<tr>
<td>Zero bleeds, % pts (95% CI)</td>
<td>62.9 (44.9; 78.5)</td>
<td>87.0 (66.4; 97.2)</td>
<td>55.6 (38.1; 72.1)</td>
<td>60.0 (42.1; 76.1)</td>
<td>56.1 (39.7; 71.5)</td>
</tr>
</tbody>
</table>

Clinically efficacious concentrations obtained with all 3 dosing regimens

Greater than 93% of patients preferred Hemlibra over their prior therapy

What would you prefer to take as the treatment for your hemophilia?
- Prefer my old hemophilia treatment (IV)
- Prefer Hemlibra treatment (SC)
- Have no preference

HAVEN 3
Survey was completed by 95/134 (70.9%) eligible patients (Arms A, B and D)

- Prefer Hemlibra: 93.7%
- Prefer prior therapy: 6.3%

HAVEN 4
Survey was completed by all 41 (100%) eligible patients

- Prefer Hemlibra: 100%

Mahlangu et al. WFH 2018, Pipe et al. WFH 2018
Exploratory efficacy endpoint assessed patient preference using the EmiPref survey
Hemlibra: A success story

- **Two BTDs granted by FDA**
- **Robust development program demonstrated efficacy in people with Hemophilia A with and without inhibitors to FVIII**
  - Subcutaneous dosing offers flexibility (qw, q2w and q4w)
  - Robust safety profile
Doing now what patients need next